FDAnews Drug Daily Bulletin

J&J Becomes a Little Less Social (World of DTC Marketing Blog)
More than a year after launching its Psoriasis 360 page on Facebook, the Janssen UK unit of Johnson & Johnson is closing it down due to a number of comments related to other drugs, blogger Rich Meyer writes. But “social media is not putting posts on a bulletin board then turning out the lights and going home for the day,” Meyer says. “Social media is a conversation, and as such it needs resources to stay relevant to the audience.” Unfortunately, another tool patients can use for research and communication is being stripped away. “Let’s be honest here; this is J&J, a company who is paying it’s ex-CEO over $140 million in severance even though the name J&J has become synonymous with recalls and screw ups. This is a company that has managed by spreadsheet rather than focusing on patients and customers,” Meyer adds.